Amiodarone-induced phospholipidosis: an in vivo [14C]-acetate uptake study in rat

Drug Chem Toxicol. 2002 Aug;25(3):247-54. doi: 10.1081/dct-120005887.

Abstract

Amiodarone (AD), a potent antiarrhythmic drug, is often associated with several adverse effects. It is shown to accumulate phospholipids in various tissues, and the impaired catabolism of phospholipids has been implicated in AD-induced phospholipidosis. The synthesis of phospholipids in tissues has not been dealt with. Hence, the incorporation of [14C]-acetate into phospholipids has been studied to understand the AD-induced phospholipidosis in lung and liver. A significant increase in lung and liver phospholipids was observed after 21 and 28 days of AD (175 mg/kg body weight/day) treatment. In the lung and liver, the incorporation of [14C]-acetate into all phospholipid fractions was elevated, while in the lung mitochondria phosphatidylcholine, phosphatidyl ethanolamine and the cardiolipin levels were significantly increased. The results indicate that, in addition to the impaired catabolism of phospholipid, AD treatment resulted in increased phospholipid synthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetates / pharmacokinetics
  • Amiodarone / adverse effects*
  • Amiodarone / pharmacokinetics
  • Animals
  • Anti-Arrhythmia Agents / adverse effects*
  • Anti-Arrhythmia Agents / pharmacokinetics
  • Carbon Radioisotopes
  • Liver
  • Lung
  • Male
  • Phospholipids / biosynthesis*
  • Phospholipids / blood
  • Rats
  • Rats, Wistar

Substances

  • Acetates
  • Anti-Arrhythmia Agents
  • Carbon Radioisotopes
  • Phospholipids
  • Amiodarone